Adenosquamous carcinoma of the lung
Jump to navigation
Jump to search
| Adenosquamous carcinoma of the lung | |
|---|---|
| Diagnosis in short | |
 Adenosquamous carcinoma of lung. H&E stain. | |
| LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
| Site | lung - see lung tumours |
|
| |
| Prevalence | rare |
| Clin. DDx | other lung tumours |
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
- Adenocarcinoma component (>=10% of tumour ‡).
- Squamous cell carcinoma component (>=10% of tumour ‡).
Note:
- ‡ Criteria used by individual pathologists may vary and/or may not be uniformly applied.[3]
DDx:
- Squamous cell carcinoma of the lung.
- Adenocarcinoma of the lung.
- Metastatic adenosquamous carcinoma - requires history.
Images
ASC - intermed. mag. (WC)
ASC - intermed. mag. (WC)
ASC - high mag. (WC)
ASC - very high mag. (WC)
www
- Lung adenosquamous carcinoma (webpathology.com).
- Lung adenosquamous carcinoma (flickr.com/Yale Rosen).
Sign out
Biopsy - possible adenosquamous carcinoma
Left Upper Lobe of Lung, Core Biopsy:
- NONSMALL CELL CARCINOMA, FAVOUR ADENOCARCINOMA, CANNOT EXCLUDE ADENOSQUAMOUS CARCINOMA.
Comment:
The tumour stains as follow:
POSITIVE: TTF-1, CK5/6 (focal), p63, napsin A.
NEGATIVE: (none).
The positive staining (TTF-1 and napsin A versus CK5/6 and p63) appears to be in different tumour cells.
The case was reviewed internally and there is agreement on the above interpretation.
Note:
- Cases should not be signed as adenosquamous carcinoma on biopsy, due to the percentage requirements (>=10% for both components) - see microscopic section.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.
- ↑ 3.0 3.1 Rao, N. (Jul 2014). "Adenosquamous carcinoma.". Semin Diagn Pathol 31 (4): 271-7. doi:10.1053/j.semdp.2014.06.004. PMID 25002356.
- ↑ Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, Gugger M, Schäfer SC (September 2015). "Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?". Oncotarget 6 (27): 23905–16. doi:10.18632/oncotarget.4163. PMC 4695160. PMID 26068980. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695160/.